Literature DB >> 16218262

The Functional Assessment of Anorexia/Cachexia Therapy (FAACT) Appetite Scale in veteran cancer patients.

Victor T Chang1, Qi Xia, Basil Kasimis.   

Abstract

Anorexia and appetite assessment is an important priority in supportive oncology. A series of 156 veterans participating in a hematology oncology service completed the Functional Assessment of Anorexia/Cachexia Therapy (FAACT), the Functional Assessment of Cancer Therapy-General scale, the Memorial Symptom Assessment Scale Short Form (MSAS-SF), and the Zung Self-Rating Depression Scale and were followed for survival. The FAACT score correlated well with Karnofsky performance status, quality of life, and symptom distress subscales. A single appetite distress item from the MSAS-SF correlated well with these measures. Both appetite measures correlated with the presence of other symptoms and with concurrently measured hemoglobin, serum sodium, albumin, and cholesterol levels. These self-reported appetite measures were univariate predictors of survival and contributed additional prognostic information to data related to weight-loss distress. In a smaller study, the FAACT score correlated with a visual analogue measure of appetite and with the North Center Cancer Treatment Group appetite instrument. These data support use of these tools for the evaluation of appetite concerns among patients with advanced cancer.

Entities:  

Mesh:

Year:  2005        PMID: 16218262

Source DB:  PubMed          Journal:  J Support Oncol        ISSN: 1544-6794


  11 in total

1.  Symptoms in advanced pancreatic cancer are of importance for energy intake.

Authors:  Asta Bye; Marit S Jordhøy; Grete Skjegstad; Oddlaug Ledsaak; Per Ole Iversen; Marianne Jensen Hjermstad
Journal:  Support Care Cancer       Date:  2012-06-10       Impact factor: 3.603

Review 2.  A systematic review of health-related quality of life instruments in patients with cancer cachexia.

Authors:  Sally Wheelwright; Anne-Sophie Darlington; Jane B Hopkinson; Deborah Fitzsimmons; Alice White; Colin D Johnson
Journal:  Support Care Cancer       Date:  2013-06-25       Impact factor: 3.603

3.  Quality of life and anorexia/cachexia in lung cancer: validation of the Spanish version of the FAACT instrument.

Authors:  Oscar Arrieta; Julissa Luvián-Morales; Jenny G Turcott; Luis F Oñate-Ocaña
Journal:  Qual Life Res       Date:  2018-07-10       Impact factor: 4.147

4.  Can anorexia predict patient satisfaction with quality of life in advanced cancer?

Authors:  Christopher G Lis; Digant Gupta; James F Grutsch
Journal:  Support Care Cancer       Date:  2008-04-02       Impact factor: 3.603

Review 5.  Evolving classification systems for cancer cachexia: ready for clinical practice?

Authors:  David Blum; Aurelius Omlin; Ken Fearon; Vickie Baracos; Lukas Radbruch; Stein Kaasa; Florian Strasser
Journal:  Support Care Cancer       Date:  2010-03       Impact factor: 3.603

6.  Progressive resistance training in cachectic head and neck cancer patients undergoing radiotherapy: a randomized controlled pilot feasibility trial.

Authors:  Manuel Grote; Cornelius Maihöfer; Martin Weigl; Patricia Davies-Knorr; Claus Belka
Journal:  Radiat Oncol       Date:  2018-11-06       Impact factor: 3.481

7.  An exploration of the prevalence and experience of cardiac cachexia: protocol for a mixed methods cross-sectional study.

Authors:  Matthew A Carson; Joanne Reid; Loreena Hill; Lana Dixon; Patrick Donnelly; Paul Slater; Alyson Hill; Donna Fitzsimons
Journal:  BMC Palliat Care       Date:  2019-10-20       Impact factor: 3.234

8.  Cancer cachexia induces morphological and inflammatory changes in the intestinal mucosa.

Authors:  Raquel G F Costa; Paula L Caro; Emídio M de Matos-Neto; Joanna D C C Lima; Katrin Radloff; Michele J Alves; Rodolfo G Camargo; Ana Flávia M Pessoa; Estefania Simoes; Patrícia Gama; Denise C Cara; Aloísio S F da Silva; Welbert O Pereira; Linda F Maximiano; Paulo S M de Alcântara; José P Otoch; Giorgio Trinchieri; Alessandro Laviano; Maurizio Muscaritoli; Marília Seelaender
Journal:  J Cachexia Sarcopenia Muscle       Date:  2019-07-15       Impact factor: 12.910

9.  A randomised, double blind, placebo-controlled trial of megestrol acetate or dexamethasone in treating symptomatic anorexia in people with advanced cancer.

Authors:  David C Currow; Paul Glare; Sandra Louw; Peter Martin; Katherine Clark; Belinda Fazekas; Meera R Agar
Journal:  Sci Rep       Date:  2021-01-28       Impact factor: 4.379

Review 10.  Molecular mechanisms of cancer cachexia‑induced muscle atrophy (Review).

Authors:  Wei Yang; Jianhui Huang; Hui Wu; Yuqing Wang; Zhiyin Du; Yuanbo Ling; Weizhuo Wang; Qian Wu; Wenbin Gao
Journal:  Mol Med Rep       Date:  2020-10-16       Impact factor: 2.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.